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Abstract 
[Background]  Although several reports have shown the efficacy of a fluorescence 
navigation system (FNS) with indocyanine green (ICG) to detect liver malignancies 
during hepatectomy, the real accuracy of this procedure is not yet clear. This study 
aimed to analyze the actual efficacy of ICG-FNS in cirrhotic and non-cirrhotic livers. 
 [Methods]  Ten cirrhotic whole livers explanted from liver transplant recipients and 
twenty-three non-cirrhotic livers from patients who underwent hepatectomy for various 
kinds of liver tumors were investigated with ICG-FNS. All surgical specimens were 
analyzed macroscopically and pathologically.  
[Results] In the patients with a cirrhotic liver, most nodules illuminated by ICG-FNS 
were diagnosed as regenerative nodules pathologically. The positive predictive value 
was 5.4%. There was a significant difference in positive predictive value to detect 
malignant liver tumors between cirrhotic liver and non-cirrhotic liver (5.4% vs 100%, 
p<0.0001). In the non-cirrhotic livers, eleven of thirty-three (32.4%) tumors were not 
recognized by ICG-FNS through the liver surface before resection. There was a 
significant difference in the depth from the liver surface to tumor between illuminated 
nodules and non-illuminated nodules (1.5 mm vs 11.6 mm, p<0.01). 
[Conclusions] It is necessary to know the limitation of ICG-FNS when detecting liver 
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Introduction 
In liver surgery, in order to achieve absolute removal of tumors, it is essential to 
recognize even small tumors and to ensure the accurate surgical margin intraoperatively. 
Intraoperative ultrasonography has been the gold standard to detect liver tumors since it 
was introduced by Makuuchi et al.1). Recently, several reports have shown the efficacy 
of intraoperative navigation surgery using a fluorescence navigation system with 
indocyanine green (ICG-FNS) 2)3). 
ICG-FNS has generally been used to detect the sentinel lymph nodes in the 
breast4) 5), gastric6)7)8), lung9)10), and esophageal cancers11) and to intraoperatively assess 
graft patency in vascular surgery12)13). The adaption of ICG-FNS was expanded for 
hepatobiliary surgery3)14)15). Ishizawa et al. 2) reported that fluorescence intraoperative 
cholangiography with ICG is a safe and valuable procedure for a road map of biliary 
tract anatomy and identification of liver tumor through the visualization of the 
disordered biliary excretion of ICG in real time. However, the actual efficacy of 
ICG-FNS to detect liver tumors is not clear. For example, false positive detection might 
occur because regenerative nodules develop as liver damage progresses16). Also, small 
tumors located deep in the liver parenchyma might not be detected by this procedure.  
Therefore, the aim of this study was to evaluate the actual efficacy of ICG-FNS in 
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cirrhotic or non-cirrhotic liver separately.  
Materials and Methods 
Patients 
Ten cirrhotic whole livers were obtained from living donor liver transplant 
(LDLT) recipients. The original diseases included hepatitis C virus (HCV)-cirrhosis in 8, 
hepatitis B virus (HBV)-cirrhosis in 1, and alcoholic cirrhosis in 1. Patient 
characteristics are listed in Table 1. In addition, we evaluated twenty-three non-cirrhotic 
liver specimens obtained from patients who underwent hepatectomy for various kind of 
liver tumors [ hepatocellular carcinoma (HCC) in 12, metastasis of colorectal cancer in 
9, cholangiocarcinoma in 1, and hepatic carcinoid in 1] (Table 1). 
 Examination methods 
As a fluorescence source, we used ICG (Diagnogreen, Daiichi Sankyo, Tokyo, 
Japan), which had been intravenously injected before surgery at a dose of 0.5mg per of 
body weight as part of a routine liver function test. The intervals between the ICG 
injection and surgery ranged from 2 days. As a fluorescent imaging tool, we used Photo 
Dynamic Eye-II (PDE-II, Hamamatsu Photonics, Hamamatsu, Japan), which filtered out 
light with a wavelength below 820 nm, and 36 light-emitting diodes with a wavelength 
of 760 nm. The camera imaging head was positioned between 20 and 30 cm above the 
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surgical specimen. The marking suture was performed near the site of the illuminated 
nodules during ten minutes while putting the emission of light situation in the video. 
Any illuminated nodules clearly visualized from the liver surface regardless of signal 
intensity, size and illuminated pattern were marked. The recognition of the illuminated 
nodules was clarified by two independent surgeons (T.T. and I. M.). Surgical specimens 
were observed from every angle, and cut to include each tumor’s maximum diameter 
based on gross inspection. After the operation, the number of the illuminated lesions in 
the video and the number of the marking sites were counted and macroscopically 
analyzed. In addition, the number of illuminated lesions which were detected through 
the liver surface and the number of identifiable tumors by pathological examination 
were analyzed. 
 Statistical analysis 
 Results for continuous variables are expressed as the median (range). The 
positive predictive value was calculated as the number of pathological tumors in 
illuminated nodules. Data for continuous variables were compared using the 
Mann-Whitney U test. We set statistical significance at p< .05.  
Results 
The efficacy of ICG-FNS to detect HCCs in a cirrhotic liver 
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The median number of preoperatively detected tumors with various 
modalities in the 10 patients with cirrhotic liver was 2 (0-4). However, as shown in 
Figure 1, the median number of illuminated nodules was 20 (7-37), and the median 
number of nodules to be macroscopically considered as tumors was 16 (3-25). The 
number of pathologically diagnosed as tumors was 2 (0-8), so the positive predictive 
value was only 5.4% (0-24.2%). The number of false negatives was 14(4-17). There 
were significant differences between the numbers of preoperatively detected tumors and 
the number of both illuminated nodules and those macroscopically recognized as tumors, 
as shown in Figure 1 (p<0.001). Moreover, there were also significant differences 
between the numbers of nodules pathologically diagnosed as tumors and the number of 
both illuminated nodules and nodules macroscopically recognized as tumors (p<0.001). 
HCC on the liver surface with ICG-FNS revealed fluorescence in Fig 2A. The area that 
was actually illuminated was also macroscopically observed as HCC in Fig 2B. The 
same part was pathologically diagnosed as HCC in Fig 2C. However, the other areas 
that were illuminated and observed as nodules were diagnosed as regenerative nodules 
(Fig 2D-F). 
The efficacy of ICG-FNS to detect malignant tumors in a non-cirrhotic liver 
The median number of preoperatively detected tumors with various modalities 
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in twenty-three patients with non-cirrhotic liver was 1 (1-4). The median number of 
illuminated nodules and nodules macroscopically recognized as tumors was 1 (0-3) and 
1 (1-4), respectively. Finally, the median number of nodules pathologically diagnosed as 
liver tumors was 1 (1-4), so that the positive predictive value to detect malignant tumors 
was 100%. There were no significant differences between the groups (Supplemental 
Figure 1). There was a significant difference in positive predictive value to detect HCC 
or malignant tumors between the cirrhotic livers and the non-cirrhotic livers (5.4% vs 
100%; p<0.0001). Although some tumors could be detected from the liver surface (Fig 
3A, B) and positive predictive value to detect malignant tumors in the non-cirrhotic 
livers was 100%, other tumors could not be detected from the liver surface (11/34, 
32.4%). These nodules were finally recognized after the liver was cut, including tumors 
(Fig3C, D) and defined as non-illuminated nodules. There was a significant difference 
in the median depth from the liver surface between illuminated nodules (n=23) and 
non-illuminated nodules (n=11) (1.5mm vs 11.6mm, p<0.01) (Fig 4A). Although there 
was no significant difference, non-illuminated nodules tended to be smaller than 
illuminated nodules (illuminated nodules, 32.4mm vs non-illuminated nodules, 
20.7mm; p=0.058) (Fig 4B). Furthermore, the tumor size of almost all non-illuminated 
nodules located within 10mm depth tended to be smaller than 10mm (Figure 4C). 
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Discussion 
ICG is usually used to directly measure the actual functional state of the liver 
17). ICG is a water-soluble, inert compound that is injected intravenously. It mainly 
binds to plasma proteins, is taken up by hepatocytes, and is excreted unchanged into the 
bile. Moreover, ICG is known to absorb infrared rays18). Lights, and specially 
near-infrared light (NIR) in the biological window (700-900nm), can be exploited for 
intraoperative imaging guidance. Tanaka et al. demonstrated that (1) the appearance of 
the surgical field is not altered, (2) it is safe, (3) wavelengths in the 800nm range 
penetrate relatively deeply into living tissue, and (4) there has been a tremendous recent 
effort in developing general-purpose NIR fluorophores that can be conjugated to 
targeting or other molecules, thus creating “contrast agents” matched to any desired 
surgical application19). Therefore, ICG injection combined with FNS is widely used to 
detect sentinel lymph nodes 4)-11), because this technique is convenient and safe for 
assessing lymph node status in the oncological field. Recently, adaptation of ICG-FNS 
was expanded further to hepatobiliary surgery and there have been some reports of its 
capability in detecting tumors 2)3). Furthermore, several reports also showed that 
ICG-FNS was effective to check the bile leakage and the surgical margin 2)3)14)15). 
Our team sectioned whole livers with HCC removed from recipients who 
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underwent living donor liver transplantation and fully investigated them to detect small 
HCCs20). Generally, hepatocytes have the ability to reproduce by themselves even if the 
hepatocytes are exposed to disorders. However, when hepatocytes are exposed to 
inflammation for a long time and repeatedly, hyperplasia of the collagen fiber deposits 
occurs strongly and many benign nodules, such as regenerative nodules, in a cirrhotic 
liver appear surrounded by collagen fiber in the extra-cellular matrix. In addition, the 
structure of the hepatic lobule is disturbed and the function of hepatocytes is affected 21). 
On the other hand, as described above, ICG binds to plasma proteins, one of which is 
ligandin. Ligandin is the binding protein of ICG and is uniformly distributed over 
hepatocytes in a normal liver. The expression of ligandin deviates with liver damage, 
and it is not expressed in areas of necrosis, fibrosis, or severe inflammation, so that the 
expression of ligandin becomes relatively rich in the regenerative area22). Finally, the 
coloration of ICG is thought to accumulate in the regenerative nodules 16).In fact, in our 
series of cirrhotic livers, many false positive nodules were illuminated, possibly because 
of the severe liver function disorder and the biliary excretion disorders2)16)21)22). 
However, Ishizawa et al. demonstrated that the signal intensity of the noncancerous 
liver parenchyma was higher in patients with an unfavorable ICG retention rate and in 
patients who had received the ICG injection within 24 hours before surgery 2). Although 
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the interval longer than 2 days might be better to obtain a good lesion-to-liver contrast, 
especially in patients with advanced cirrhosis, we routinely perform the ICG test when 
the patients hospitalized generally 2 days before the operation. Also, the optimal 
interval between ICG injection and surgery to detect tumors remains controversial.  
Secondly, we attempted to evaluate liver resection cases with non-cirrhotic livers. 
The aim of this study was to determine whether fluorescence navigation system was 
effective or not to detect tumors. Therefore, we did not evaluate the illuminated pattern 
of tumors. However, we got the same results as Ishizawa’s report concerning with 
illuminated pattern of liver tumors (data not shown)2).It was clear that although false 
positive nodules were not observed in the non-cirrhotic livers, smaller tumors and 
tumors that were located deeper than 10mm from liver surface to tumor were difficult to 
recognize as illuminated nodules. Kim et al have already described that near-infrared 
light penetrates human tissues to a depth of about 5-10 mm and Ishizawa et al. have also 
described that cancer detectability using fluorescent imaging technique seems mainly to 
depend on the depth of the tumors from the liver surface because of the limited tissue 
penetration of near-infrared light 2)23). Therefore, in our study, ICG-FNS wasn’t able to 
detect tumors located deeper than 10mm. Possibly, 10mm is the maximum limit of 
depth for ICG-FNS to detect tumors. Based on these results, we suggested that the 
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capability of detecting tumors with ICG-FNS alone was not sufficient in both cirrhotic 
and non-cirrhotic livers. 
 We conclude that although ICG-FNS have the capability of detecting tumors 
and checking the bile leakage and surgical margin, it is necessary to know the limitation 
of ICG-FNS when searching liver malignancies in cirrhotic livers or small and deep 
liver malignancies in non-cirrhotic livers. Additional modalities including ultrasound 
should be adapted for use with this procedure to detect small liver tumors. 
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Figure Legends 
Figure 1: The number of detected nodules in a cirrhotic liver 
The median number of preoperative, illuminated, macroscopic, pathological tumors 
with cirrhotic liver was, in order, 2 (0-4), 20 (7-37), 16 (3-25), and 2 (0-8). There were 
significant differences between preoperative tumors and both illuminated nodules and 
macroscopic tumor (p<0.001). Moreover, there were also significant differences 
between pathological tumor and both illuminated nodules and macroscopic tumor 
(p<0.001). 
Figure 2: ICG-FNS for patients with cirrhotic liver and pathological results 
A, HCCs on the liver surface with ICG-FNS revealed the illuminated nodules. B, The 
area that actually emitted light was also macroscopically observed as liver tumor. C, 
The same area was pathologically diagnosed as HCC. D, The other areas on the liver 
surface in the same case also revealed the illuminated nodules. E, The areas that emitted 
light were macroscopically observed as nodules. F, Finally, these areas were diagnosed 
as regenerative nodules. 
Figure 3: ICG-FNS for patients with liver resection with non-cirrhotic liver. 
Liver tumors in illuminated nodules could be observed as illuminated nodules on the 
liver surface (Figure 3A-B); liver tumors in non-illuminated nodules could not be 
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observed as illuminated lesions on the surface, and finally recognized after the liver was 
cut including the tumor under US guidance (Fig3C-D). 
Figure 4: Comparison between illuminated nodules and non-illuminated nodules on the 
liver surface in a non-cirrhotic liver 
A: There was a significant difference in median depth from the liver surface between 
illuminated nodules and non-illuminated nodules (1.5mm vs 11.6mm, p<0.01). B: 
Non-illuminated nodules tended to be smaller than illuminated nodules (illuminated 
nodules, 32.4mm vs non-illuminated nodules, 20.7mm; p=0.058). C: Correlation 
diagram of the depth and tumor size presented. The tumor size of almost all 
non-illuminated nodules located within 10mm depth tended to be smaller than 10mm. 
 
Supplemental Figure 1: Number of detected nodules in a non-cirrhotic liver  
The median number of preoperative, illuminated, macroscopic, and pathological tumors 
with non-cirrhotic liver was, in order, 1 (1-4), 1 (0-3), 1 (1-4), and 1 (1-4). There were 
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 Table 1: The charactaristics of patients with a cirrhotic liver and a non-cirrhotic liver  
 cirrhotic liver for LDLT 
(n=10) 
non-cirrhotic liver for liver resection 
(n=23) 
Gender ( Male: Female) 6:4 16:7 
Age* 61(38-72) 67.5(60-90) 
liver disease HCV:8,  HBV:1,alchohol:1 HCV:5, HBV:5, NBNC:4, NL:9 
liver tumor HCC:9 HCC:12,  metastases：9, CCC：1, 
Carcinoid：1 
Total-bilirubin(mg/dl)* 3.2(0.5-8.8) 0.8(0.3-1.4) 
AST(IU/l)* 52(30-89) 28(13-285) 
ALT(IU/l)* 29(15-75) 27(10-100) 
Albumin(g/dl)* 2.6(2.1-3.8) 4.2(2.9-5.2) 
Platetlet(x104/mm3)* 6.4(2.3-13.4) 16.4(10.8-27.6) 
PT(INR)* 1.47(1.07-1.95) 1.00(0.87-1.13) 
ICGR15(%)* 44(24-70) 11(2-15) 
Child-Pugh score* 9(5-12) 5(5-7) 
MELD score* 14(7-22) - 
HCV: Hepatitis C virus, HBV: Hepatitis B virus, NBNC:non-HBV non HCV,  
NL: normal liver, HCC: Hepatocellular carcinoma, CCC: cholangiocarcinoma, 
AST: aspartate aminotransferase, ALT: alanine aminotransferase,  
PT: prothorombin time, INR: international normalized ratio,  
ICGR15: indocyanine green retention rate at 15 minutes,  
MELD score: model for endstage liver disease score 




Figure 1: The number of detected nodules in a cirrhotic liver.





















Figure 2: ICG-FNS for patients with cirrhotic liver and pathological results.
Figure 3: ICG-FNS for patients with liver resection with non-cirrhotic liver.
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